tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ideaya Biosciences enrolls first patient in IDE397 trial

Ideaya Biosciences (IDYA) announced they have enrolled their first patient with non-small cell lung cancer in the ongoing Phase 1/2 combination trial of IDE397, a small molecule adenosyltransferase 2a inhibitor, and Trodelvy, a Trop2-directed antibody-drug conjugate, in patients with methylthioadenosine phosphorylase-deletion solid tumors. Ideaya is conducting the trial pursuant to a clinical study collaboration and supply agreement with Gilead (GILD), where the initial focus was in MTAP-deletion urothelial cancer. In April, the companies announced expansion of the combination trial into MTAP-deletion NSCLC.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1